Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease

Leucine-rich repeat kinase-2 (LRRK2)
mutations are a common cause of
Parkinson's disease. Here we identify
inhibitors of LRRK2 kinase that are
protective in in vitro and in vivo models
of LRRK2-induced neurodegeneration.
These results establish that LRRK2-
induced degeneration of neurons in vivo
is kinase dependent and that LRRK2
kinase inhibition provides a potential
new neuroprotective paradigm for the
treatment of Parkinson's disease.









Nature Medicine 16, 998 - 1000 (2010)
Published online: 22 August 2010 | doi:10.1038/nm.2199